Pharvaris (PHVS) Competitors $20.00 +0.12 (+0.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.08 +0.07 (+0.37%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ADMA, KRYS, MTSR, ABVX, ZLAB, AKRO, ACLX, ACAD, VKTX, and SRRKShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include ADMA Biologics (ADMA), Krystal Biotech (KRYS), Metsera (MTSR), Abivax (ABVX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors ADMA Biologics Krystal Biotech Metsera Abivax Zai Lab Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock ADMA Biologics (NASDAQ:ADMA) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Do insiders & institutionals believe in ADMA or PHVS? 75.7% of ADMA Biologics shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings and valuation, ADMA or PHVS? ADMA Biologics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M10.82$197.67M$0.8522.74PharvarisN/AN/A-$145.24M-$3.01-6.64 Which has more volatility and risk, ADMA or PHVS? ADMA Biologics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, suggesting that its stock price is 381% less volatile than the S&P 500. Is ADMA or PHVS more profitable? ADMA Biologics has a net margin of 45.01% compared to Pharvaris' net margin of 0.00%. ADMA Biologics' return on equity of 47.16% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics45.01% 47.16% 30.51% Pharvaris N/A -54.02%-50.36% Do analysts rate ADMA or PHVS? ADMA Biologics currently has a consensus price target of $27.67, suggesting a potential upside of 43.13%. Pharvaris has a consensus price target of $36.20, suggesting a potential upside of 81.00%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ADMA or PHVS? In the previous week, ADMA Biologics had 7 more articles in the media than Pharvaris. MarketBeat recorded 10 mentions for ADMA Biologics and 3 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.88 beat ADMA Biologics' score of 0.81 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryADMA Biologics beats Pharvaris on 12 of the 16 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-6.6417.7428.8623.83Price / SalesN/A178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book3.618.508.275.54Net Income-$145.24M-$55.06M$3.25B$259.28M7 Day Performance-3.01%-3.99%-3.73%-4.68%1 Month Performance12.23%9.58%4.29%4.36%1 Year Performance23.61%6.70%25.87%17.89% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.7483 of 5 stars$20.00+0.6%$36.20+81.0%+25.5%$1.04BN/A-6.6430ADMAADMA Biologics4.289 of 5 stars$18.00-0.1%$27.67+53.7%+57.7%$4.30B$426.45M21.18530Upcoming EarningsKRYSKrystal Biotech4.8923 of 5 stars$152.91+3.6%$211.33+38.2%-21.0%$4.27B$290.52M36.76210Upcoming EarningsMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.25BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap DownABVXAbivax3.6049 of 5 stars$66.57+0.1%$85.33+28.2%+511.7%$4.22BN/A0.0061News CoverageAnalyst ForecastGap DownZLABZai Lab2.3998 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.13B$398.99M-15.541,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap UpAKROAkero Therapeutics3.9559 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A-25.2530Positive NewsUpcoming EarningsACLXArcellx2.6002 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.93B$107.94M-23.6180News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9847 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.89B$957.80M16.51510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.8674 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.87BN/A-21.7020Short Interest ↑SRRKScholar Rock3.8123 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.70B$33.19M-14.66140News CoveragePositive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies ADMA Biologics Alternatives Krystal Biotech Alternatives Metsera Alternatives Abivax Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives Arcellx Alternatives ACADIA Pharmaceuticals Alternatives Viking Therapeutics Alternatives Scholar Rock Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
